134 related articles for article (PubMed ID: 2924297)
1. Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium.
Gibbons GR; Wyrick S; Chaney SG
Cancer Res; 1989 Mar; 49(6):1402-7. PubMed ID: 2924297
[TBL] [Abstract][Full Text] [Related]
2. An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.
Chaney SG; Gibbons GR; Wyrick SD; Podhasky P
Cancer Res; 1991 Feb; 51(3):969-73. PubMed ID: 1988140
[TBL] [Abstract][Full Text] [Related]
3. In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma.
Chaney SG; Wyrick S; Till GK
Cancer Res; 1990 Aug; 50(15):4539-45. PubMed ID: 2196115
[TBL] [Abstract][Full Text] [Related]
4. Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses.
Carfagna PF; Poma A; Wyrick SD; Holbrook DJ; Chaney SG
Cancer Chemother Pharmacol; 1991; 27(5):335-41. PubMed ID: 1998992
[TBL] [Abstract][Full Text] [Related]
5. Effects of diethyldithiocarbamate (DDTC) on the plasma biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in Fischer 344 rats.
Carfagna PF; Wyrick SD; Holbrook DJ; Chaney SG
J Biochem Toxicol; 1991; 6(1):71-80. PubMed ID: 1652641
[TBL] [Abstract][Full Text] [Related]
6. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.
Mauldin SK; Gibbons G; Wyrick SD; Chaney SG
Cancer Res; 1988 Sep; 48(18):5136-44. PubMed ID: 3409241
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH
Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287
[TBL] [Abstract][Full Text] [Related]
8. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.
Pendyala L; Creaven PJ
Cancer Res; 1993 Dec; 53(24):5970-6. PubMed ID: 8261411
[TBL] [Abstract][Full Text] [Related]
9. Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.
Mauldin SK; Husain I; Sancar A; Chaney SG
Cancer Res; 1986 Jun; 46(6):2876-82. PubMed ID: 3698013
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue.
Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV
Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402
[TBL] [Abstract][Full Text] [Related]
11. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
Kido Y; Khokhar AR; al-Baker S; Siddik ZH
Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
[TBL] [Abstract][Full Text] [Related]
13. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
[TBL] [Abstract][Full Text] [Related]
14. Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II).
Rischin D; Ling V
Br J Cancer; 1996 Aug; 74(4):590-6. PubMed ID: 8761375
[TBL] [Abstract][Full Text] [Related]
15. Glutathione-mediated modulation of tetraplatin activity against sensitive and resistant tumor cells.
Kido Y; Khokhar AR; Siddik ZH
Biochem Pharmacol; 1994 Apr; 47(9):1635-42. PubMed ID: 8185678
[TBL] [Abstract][Full Text] [Related]
16. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
[TBL] [Abstract][Full Text] [Related]
17. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
[TBL] [Abstract][Full Text] [Related]
18. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
19. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
Anticancer Drug Des; 1994 Dec; 9(6):495-509. PubMed ID: 7880375
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravenously injected [3H]tetrachloro(D,L-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin) in mice.
Kido Y; Khokhar AR; Siddik ZH
Drug Metab Dispos; 1992; 20(5):673-8. PubMed ID: 1358571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
